Aviso Financial Inc. Has $2.95 Million Position in AstraZeneca PLC $AZN

Aviso Financial Inc. lifted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 5.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,228 shares of the company’s stock after buying an additional 2,249 shares during the period. Aviso Financial Inc.’s holdings in AstraZeneca were worth $2,951,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. NewSquare Capital LLC boosted its position in AstraZeneca by 149.3% during the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after purchasing an additional 218 shares during the last quarter. Richardson Financial Services Inc. raised its stake in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after purchasing an additional 149 shares in the last quarter. Costello Asset Management INC acquired a new stake in shares of AstraZeneca in the 1st quarter valued at approximately $29,000. FSA Wealth Management LLC grew its stake in shares of AstraZeneca by 376.0% in the second quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after buying an additional 376 shares in the last quarter. Finally, VSM Wealth Advisory LLC acquired a new position in AstraZeneca during the second quarter worth $33,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on AZN shares. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Finally, Jefferies Financial Group initiated coverage on AstraZeneca in a report on Monday, October 27th. They set a “buy” rating for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Stock Up 0.6%

Shares of NASDAQ AZN opened at $91.52 on Tuesday. The stock has a market capitalization of $283.84 billion, a P/E ratio of 34.41, a PEG ratio of 1.52 and a beta of 0.34. The stock’s fifty day moving average is $83.27 and its 200 day moving average is $77.05. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $91.90. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. During the same period in the prior year, the company posted $2.08 earnings per share. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. Sell-side analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.